Cabotamig is under clinical development by Arbele and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cabotamig’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cabotamig overview

Cabotamig (ARB-202) is under development for the treatment of refractory pancreatic cancer, refractory bile duct cancer (cholangiocarcinoma), stomach cancer, gastrointestinal tumor, liver, colorectal  and colon cancer. It is a Bi-specific T-cell engager (BiTE) monoclonal antibody acts by targeting CDH17/CD3 (cadherin-17/CD3).

Arbele overview

Arbele is a biopharmaceutical company that discovers and develops immunotherapeutics for the treatment of cancers, immune disorders and neurological diseases. Arbele is headquartered in Hong Kong.

For a complete picture of Cabotamig’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.